DURECT Corporation Announces Publication of Larsucosterol Phase 2b Results in NEJM Evidence

The article presents new trial data, including subgroup analyses and liver biomarkers, which have guided the design of the Company's planned Phase 3 trialCUPERTINO, Calif., Jan. 28, 2025 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today announced the publication of a peer-reviewed article on the AHFIRM trial data in NEJM Evidence. The full article, entitled, "Larsucosterol for the Treatment of Alcohol-Associated Hepatitis," can be accessed here.The AHFIRM trial was a Phase 2b randomized, double-blind, ...